The role of chemotherapy in the treatment of central neurocytoma.
dc.contributor.author | Johnson, Margaret O | |
dc.contributor.author | Kirkpatrick, John P | |
dc.contributor.author | Patel, Mallika P | |
dc.contributor.author | Desjardins, Annick | |
dc.contributor.author | Randazzo, Dina M | |
dc.contributor.author | Friedman, Henry S | |
dc.contributor.author | Ashley, David M | |
dc.contributor.author | Peters, Katherine B | |
dc.date.accessioned | 2020-08-28T19:26:19Z | |
dc.date.available | 2020-08-28T19:26:19Z | |
dc.date.issued | 2019-11-05 | |
dc.date.updated | 2020-08-28T19:26:17Z | |
dc.description.abstract | Aim: Central neurocytoma (CN) is a rare WHO grade II central nervous system (CNS) tumor. This is an update on chemotherapeutic agents used in its treatment. Patients & methods: An institutional review board-approved, chart review of patients seen at our institution resulted in a single case treated with chemotherapy and is herein included. We proceeded with a comprehensive literature review. Results: We identified 18 citations, representing 39 cases of adult and pediatric CN treated with chemotherapy. With the addition of our single case, the total number of recurrent CN patients treated with temozolomide (TMZ) is nine. Conclusion: There exists marked heterogeneity in chemotherapy used to treat CN. TMZ is incorporated into treatment regimens in the setting of tumor recurrence: its role merits further study. | |
dc.identifier.issn | 2045-0907 | |
dc.identifier.issn | 2045-0915 | |
dc.identifier.uri | ||
dc.language | eng | |
dc.publisher | Future Medicine Ltd | |
dc.relation.ispartof | CNS oncology | |
dc.relation.isversionof | 10.2217/cns-2019-0012 | |
dc.subject | Humans | |
dc.subject | Neurocytoma | |
dc.subject | Brain Neoplasms | |
dc.subject | Antineoplastic Agents | |
dc.subject | Treatment Outcome | |
dc.title | The role of chemotherapy in the treatment of central neurocytoma. | |
dc.type | Journal article | |
duke.contributor.orcid | Johnson, Margaret O|0000-0003-1208-622X | |
duke.contributor.orcid | Kirkpatrick, John P|0000-0002-4019-0350 | |
duke.contributor.orcid | Randazzo, Dina M|0000-0002-3394-656X | |
duke.contributor.orcid | Friedman, Henry S|0000-0001-7588-032X | |
pubs.begin-page | CNS41 | |
pubs.issue | 3 | |
pubs.organisational-group | School of Medicine | |
pubs.organisational-group | Duke Cancer Institute | |
pubs.organisational-group | Pathology | |
pubs.organisational-group | Pediatrics | |
pubs.organisational-group | Medicine, Medical Oncology | |
pubs.organisational-group | Duke | |
pubs.organisational-group | Institutes and Centers | |
pubs.organisational-group | Clinical Science Departments | |
pubs.organisational-group | Medicine | |
pubs.organisational-group | Radiation Oncology | |
pubs.organisational-group | Neurosurgery | |
pubs.organisational-group | Pediatrics, Neurology | |
pubs.organisational-group | Neurology, General & Community Neurology | |
pubs.organisational-group | Neurology | |
pubs.publication-status | Published | |
pubs.volume | 8 |
Files
Original bundle
- Name:
- The role of chemotherapy in the treatment of central neurocytoma.pdf
- Size:
- 691.94 KB
- Format:
- Adobe Portable Document Format
- Description:
- Published version